Current and future treatments in progressive supranuclear palsy

  title={Current and future treatments in progressive supranuclear palsy},
  author={Irene van Balken and Irene Litvan},
  journal={Current Treatment Options in Neurology},
Opinion statementProgressive supranuclear palsy (PSP) is an atypical parkinsonian disorder that, in spite of its growing recognition, is still underdiagnosed. For management, prognosis, and research, an accurate and early diagnosis is essential. PSP is a relentlessly progressive neurodegenerative disorder, clinically characterized by parkinsonism with prominent axial involvement and postural instability, bulbar symptoms, supranuclear ophthalmoplegia, and executive dysfunction. Abnormal neuronal… Expand
Therapeutic options for Progressive Supranuclear Palsy including investigational drugs
The most important therapeutic targets for PSP patients are discussed based on the hypothesized pathogenesis of the disease and most of the current symptomatic therapeutic approaches are based on small double-blind, placebo control studies, or open trials. Expand
A Review of Treatment Options for Progressive Supranuclear Palsy
The evidence on pharmacotherapy and experimental therapies ingressive supranuclear palsy is reviewed and levels of recommendation for the off-label use of commonly used drugs in this disorder are provided. Expand
Preclinical, phase I, and phase II investigational clinical trials for treatment of progressive supranuclear palsy
Disease-modifying therapeutic options which are currently under evaluation or have been evaluated in preclinical or clinical trials based on their targeted pathophysiologic process are discussed. Expand
Title Preclinical , phase I , and phase II investigational clinical trials for treatment of progressive supranuclear palsy
Introduction: Our understanding of the pathological basis of progressive supranuclear palsy (PSP), as the most common atypical parkinsonian syndrome, has greatly increased in recent years and aExpand
Mitochondrial Dysfunction as a Therapeutic Target in Progressive Supranuclear Palsy
It is suggested that a failure in mitochondrial energy production might act as an upstream event in the chain of pathological events leading to the aggregation of tau and neuronal cell death in PSP. Expand
Concomitant Medication Use in Progressive Supranuclear Palsy Clinical Trial Participants
Progressive Supranuclear Palsy (PSP) is a rare and progressive movement disorder pathologically characterized by tau tangles for which there are no effective therapies. Emerging therapies forExpand
Interventions in progressive supranuclear palsy.
Progressive supranuclear palsy (PSP) an atypical parkinsonian with a common phenotype comprising early falls, the characteristic slowing of vertical saccades and a frontal syndrome with marked apathyExpand
Current and future therapeutic approaches in progressive supranuclear palsy.
Since an effective therapy for PSP has yet to be found, current management should include palliative symptomatic therapies, education, and support for patients and caregivers to improve the quality of life of patients and their caregivers. Expand
Frontotemporal lobar degeneration
The clinical and pathological heterogeneity of FTLD poses a significant diagnostic challenge, and in vivo prediction of underlying histopathology can be significantly improved by supplementing the clinical evaluation with genetic tests and emerging biological markers. Expand
Functional impairment in progressive supranuclear palsy
Function disability was high in early-stage PSP, with 100% of patients having less than perfect scores on all functional scales, and the definition of functional intactness/impairment has important implications. Expand


Treatment of progressive supranuclear palsy and corticobasal degeneration
  • A. Lang
  • Medicine
  • Movement disorders : official journal of the Movement Disorder Society
  • 2005
The similarities in the molecular pathology of these four‐repeat tauopathies suggests that important advances in the management of one will have a definite impact on the treatment of the other. Expand
Autopsy-proven progressive supranuclear palsy in two siblings
These cases are the first pair of relatives reported with autopsy confirmation of PSP in both and raise the question of genetic predisposition to PSP. Expand
Progressive Supranuclear Palsy
The multiple neurotransmitter abnormalities, including those affecting dopamine, acetylcholine, γ-aminobutyric acid and norepinephrine and pathways, as well as both pre- and post-synaptic pathology, make pharmacological therapy of PSP a challenge. Expand
Pharmacological therapy in progressive supranuclear palsy.
Use of antiparkinsonian medications and other neurotransmitter replacement therapies was largely ineffective and caused frequent adverse effects in this series of patients with autopsy-confirmed with progressive supranuclear palsy. Expand
[A case of progressive supranuclear palsy improved with tandospirone citrate].
Tandospirone citrate was effective on a 74-year-old male case of progressive supranuclear palsy who responded to tandospiral citrate, a serotonin receptor (5-HT1A) agonist, suggesting that combination of levodopa and t andospir one citrate is a useful therapy for PSP. Expand
Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study
The results suggest that the true prevalence of PSP and MSA has been underestimated, since many patients in the community remain undiagnosed or misdiagnosed. Expand
Progressive supranuclear palsy presenting with dynamic aphasia.
Relatively selective involvement of cognitive processes critical for planning and initiating language output may occur in some patients with PSP, which resembles the phenomenon of "verbal adynamia" or "dynamic aphasia" seen in patients with frontal lobe damage. Expand
[A case of progressive supranuclear palsy showing improvement of rigidity, nuchal dystonia and autonomic failure with trazodone].
A 63-year-old man with a 1,5-year history of progressive dementia, supranuclear ophthalmoplegia, pseudobulbar palsy, rigidity and dystonia, and profuse sweating ameliorated after trazodone administration, illustrating a substantial role of impairments in the serotonin system in the production of some PSP symptoms. Expand
The Internal Globus Pallidus Is Affected in Progressive Supranuclear Palsy and Parkinson's Disease
Surgical ablation of the internal globus pallidus for Parkinson's disease appears at odds with the significant neurodegeneration in the similarly akinetic and rigid patients with progressive supranuclear palsy. Expand
Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism.
It is proposed that PSP-P represents a second discrete clinical phenotype that needs to be clinically distinguished from classical PSP (RS), and the different tau isoform deposition in the basal pons suggests that this may ultimately prove to be a discrete nosological entity. Expand